Table 1. Demographic and Clinical Features of Endometriosis Patients and Healthy Controlsa.
| Clinical Parameter | Endometriosis (N = 39) | Control (N = 48) | p-Value |
|---|---|---|---|
| BMI (kg/m2) | 25.00 ± 1.80 | 19.98 ± 0.99 | <0.001*** |
| Age (years <32) | 26.37 ± 2.68 | 27.02 ± 2.92 | 0.528ns |
| Age (years >32) | 42.53 ± 4.53 | 39.93 ± 6.19 | 0.200ns |
| Age at Menarche (AAM) years | 14.64 ± 1.25 | 14.03 ± 1.18 | 0.363ns |
| CA-125 (U/mL) | 46.44 ± 6.85 | 27.42 ± 2.14 | <0.001*** |
| Sugar (fasting; mg/dL) | 103.6 ± 54.00 | 89.40 ± 5.77 | 0.319ns |
| Sugar (Post Prandial; mg/dL) | 140.8 ± 43.8 | 97.77 ± 9.97 | 0.001* |
| Prolactin (PRL; ng/dL) | 12.35 ± 1.76 | 8.016 ± 0.94 | <0.001*** |
| Triiodothyronine (T3; ng/dL) | 135.67 ± 23.53 | 106.29 ± 10.00 | 0.002* |
| Thyroxine (T4, μg/dL) | 9.73 ± 2.02 | 8.56 ± 0.92 | 0.095ns |
| Thyroid-stimulating hormone (TSH; μIU/mL) | 4.69 ± 0.89 | 2.48 ± 0.49 | <0.001*** |
| Luteinizing hormone (LH; mIU/mL) | 24.40 ± 7.76 | 4.41 ± 1.40 | <0.001*** |
| Follicle-stimulating hormone (FSH; mIU/mL) | 13.57 ± 3.01 | 5.90 ± 1.01 | <0.001*** |
| LH/FSH | 1.77 ± 0.42 | 0.73 ± 0.10 | <0.001*** |
| Estradiol (E2; pg/dL) | 419.27 ± 18.45 | 46.88 ± 2.84 | <0.001*** |
| Testosterone (T; ng/dL) | 0.45 ± 0.08 | 0.43 ± 0.058 | 0.722ns |
| E2/T ratio | 0.97 ± 0.19 | 0.12 ± 0.01 | <0.001*** |
| Interleukin 6 (IL-6) | 442.92 ± 9.50 | 16.15 ± 1.26 | <0.001*** |
| Cortisol | 110.22 ± 5.69 | 91.94 ± 3.16 | <0.001*** |
a
N = total number of subjects, ns = not significant, p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Student’s t test was used to compare the mean for the endometriosis and control subjects. Two-tailed p-values less than 0.05 were considered statistically significant. Abbreviations used: BMI, body mass index; kg, kilogram; mg, milligram; μg, microgram; ng, nanogram; pg, pictogram; mL, milliliter; dL, deciliter; mIU, milli-international units; μIU, micro-international units.